Tirzepatide With Insulin Glargine Improves Type 2 Diabetes
HAMBURG, Germany ― Once-weekly tirzepatide (Mounjaro, Lilly) added to insulin glargine resulted in greater reductions in A1c along with more weight loss and less hypoglycemia compared with prandial insulin lispro (Humalog, Sanofi) for patients with inadequately controlled type 2 diabetes, show data from the SURPASS-6 randomized clinical trial. Tirzepatide led to a statistically and clinically significant reduction in mean A1c, at […]
Continue reading »